Overview

Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

Status:
Not yet recruiting

Trial end date:
2024-10-20

Target enrollment:

Participant gender:

Summary

In this study, we investigate the efficacy and safety of trastuzumab, pyrotinib combined with dalpiciclib and endocrine combination therapy for patients with advanced HR+/HER2+, providing more possible effective regimens for the survival benefit of these patients in clinical practice.

Phase:

Phase 2

Details

Lead Sponsor:

Peking University Cancer Hospital & Institute

Treatments:

Trastuzumab